Intensity Therapeutics Q4 EPS $(1.31) Misses $(0.04) Estimate

Intensity Therapeutics (NASDAQ: INTS) reported a Q4 loss of $(1.31) per share, significantly missing the analyst consensus estimate of $(0.04) by 2946.51%. This represents a 76.18% increase in losses compared to $(5.50) per share from the same period last year.